Skip to main content
. Author manuscript; available in PMC: 2014 Jul 29.
Published in final edited form as: Cancer Res. 2012 Apr 13;72(12):2937–2948. doi: 10.1158/0008-5472.CAN-11-3368

Figure 1.

Figure 1

Laboratory parameters in patients who received Ad-ISF35 IDI. A, DNA isolated from blood leukocytes of patients that received Ad-ISF35 IDI was evaluated for the presence of virus DNA by qPCR. The dotted line indicates the limit of detection of this assay (5 copies of Ad-ISF35 in 100 ng of genomic DNA). B, hemoglobin (Hb) levels and platelet counts (plt). C, absolute lymphocyte counts (ALC). D, T-cell counts (CD3+CD4+ and CD3+CD8+ subsets) and ANC of all patients over time following IDI of Ad-ISF35 are represented in the graphs. E, expression of cell surface markers in CLL cells obtained pre- and post- (1–2 days) Ad-ISF35 IDI. Error bars represent the SD. *, statistical significant difference by t test when compared with baseline level. MFI, mean fluorescence intensity.